Hyperglycemia can activate the NLRP3 inflammasome and mediate the inflammatory response of patients with DKD by ATP-P2X4 signaling, suggesting that this pathway may serve as an anti-inflammatory therapeutic target for delaying DKD [31]. This evidence concerns the gene NLRP3 and Hyperglycemia.